MENU
+Compare
URGN
Stock ticker: NASDAQ
AS OF
Apr 28 closing price
Price
$11.26
Change
+$1.40 (+14.20%)
Capitalization
519.02M

URGN UroGen Pharma Ltd Forecast, Technical & Fundamental Analysis

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers... Show more

Industry: #Biotechnology
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for URGN with price predictions
Apr 28, 2025

URGN sees its Stochastic Oscillator ascends from oversold territory

On April 11, 2025, the Stochastic Oscillator for URGN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 67 instances where the indicator left the oversold zone. In of the 67 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 22, 2025. You may want to consider a long position or call options on URGN as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for URGN just turned positive on April 28, 2025. Looking at past instances where URGN's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

URGN moved above its 50-day moving average on April 28, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where URGN advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for URGN moved out of overbought territory on March 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The 10-day moving average for URGN crossed bearishly below the 50-day moving average on April 09, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where URGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

URGN broke above its upper Bollinger Band on April 28, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for URGN entered a downward trend on April 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.234) is normal, around the industry mean (14.342). P/E Ratio (0.000) is within average values for comparable stocks, (64.236). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.830). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (5.342) is also within normal values, averaging (254.940).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. URGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. URGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

URGN is expected to report earnings to fall 1.68% to -78 cents per share on May 08

UroGen Pharma Ltd URGN Stock Earnings Reports
Q1'25
Est.
$-0.79
Q4'24
Missed
by $0.03
Q3'24
Beat
by $0.27
Q2'24
Missed
by $0.08
Q1'24
Missed
by $0.10
The last earnings report on March 10 showed earnings per share of -80 cents, missing the estimate of -76 cents. With 2.32M shares outstanding, the current market capitalization sits at 519.02M.
A.I. Advisor
published General Information

General Information

a developer of therapies for urological pathologies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
400 Alexander Park Drive
Phone
+1 646 768-9780
Employees
201
Web
https://www.urogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X94978.7500001223.914100
+1.31%
Bitcoin cryptocurrency
GME27.590.13
+0.47%
GameStop Corp
AAPL210.140.86
+0.41%
Apple
TSLA285.880.93
+0.33%
Tesla
SPY550.850.21
+0.04%
SPDR® S&P 500® ETF

URGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with RNA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
-2.37%
RNA - URGN
51%
Loosely correlated
-0.29%
MREO - URGN
43%
Loosely correlated
-1.57%
LGVN - URGN
43%
Loosely correlated
+7.36%
IDYA - URGN
42%
Loosely correlated
-0.37%
RXRX - URGN
40%
Loosely correlated
-0.35%
More